We Can Medicines Co (ROCO:6929) Other Current Payables: NT$138 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6929 We Can Medicines Co Ltd ROCO:6929
46 GF Score
Price NT$22.85
GF Value NT$40.69
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is We Can Medicines Co Other Current Payables?

We Can Medicines Co ROCO:6929 +1.11% 46 Other Current Payables is NT$138 Mil as of Dec. 2025. GuruFocus rates ROCO:6929 with a GF Score™ of 46/100 and a GF Value™ of NT$40.69 (Possible Value Trap). The stock has 4 warning signs investors should review.

We Can Medicines Co's Other Current Payables for the quarter that ended in Dec. 2025 was NT$138 Mil.

We Can Medicines Co's quarterly Other Current Payables increased from Jun. 2025 (NT$111 Mil) to Sep. 2025 (NT$117 Mil) and increased from Sep. 2025 (NT$117 Mil) to Dec. 2025 (NT$138 Mil).

We Can Medicines Co's annual Other Current Payables increased from Dec. 2023 (NT$112 Mil) to Dec. 2024 (NT$136 Mil) and increased from Dec. 2024 (NT$136 Mil) to Dec. 2025 (NT$138 Mil).

We Can Medicines Co Other Current Payables Related Terms

We Can Medicines Co Other Current Payables Historical Data

* Premium members only.

The historical data trend for We Can Medicines Co's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

We Can Medicines Co Other Current Payables Chart

We Can Medicines Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial 125.92 139.73 111.90 136.25 137.77

We Can Medicines Co Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 136.25 96.98 111.48 116.65 137.77
ROCO:6929
46GF Score
We Can Medicines Co Ltd ROCO:6929
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

We Can Medicines Co Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of NT$138 Mil mean?
We Can Medicines Co (ROCO:6929) has a Other Current Payables of NT$138 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on We Can Medicines Co and its competitors.
Is We Can Medicines Co's Other Current Payables too high?
We Can Medicines Co's current Other Current Payables is NT$138 Mil. Overall, We Can Medicines Co has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does We Can Medicines Co's Other Current Payables compare to KHC and GIS?
We Can Medicines Co's Other Current Payables of NT$138 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Consumer Packaged Goods company?
A good Other Current Payables depends on the Consumer Packaged Goods industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on We Can Medicines Co and its competitors. We Can Medicines Co's current Other Current Payables is NT$138 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is We Can Medicines Co stock overvalued right now?
Based on GuruFocus' analysis, We Can Medicines Co (ROCO:6929) is currently considered Possible Value Trap. The stock's GF Value™ is NT$40.69, compared to a current price of NT$22.85 — trading 43.8% below its estimated fair value. The current Other Current Payables is NT$138 Mil. We Can Medicines Co's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For We Can Medicines Co (ROCO:6929), the current Other Current Payables is NT$138 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is We Can Medicines Co (ROCO:6929) Overvalued in 2026?

Based on GuruFocus' analysis, We Can Medicines Co stock appears to be undervalued. The current stock price of NT$22.85 is trading 43.8% below its estimated GF Value™ of NT$40.69. GuruFocus considers We Can Medicines Co to be Possible Value Trap.

Key valuation signals for ROCO:6929:

  • Other Current Payables: NT$138 Mil
  • GF Value™: NT$40.69 vs. price of NT$22.85 (43.8% below fair value)
  • GF Score™: 46/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6929 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

We Can Medicines Co Business Description

Address Section 4, Taiwan Avenue, 20th Floor-1, No. 925, Xitun District, Taichung, TWN
We Can Medicines Co Ltd is a Taiwan-based company mainly engaged in the operation of chain cosmeceutical drugstores. The Company's main products include pharmaceuticals and health food, maternity and infant products, medical supplies, beauty cosmetics, and daily necessities.
46GF Score

Get the complete analysis for ROCO:6929

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$22.85
Price
NT$40.69
GF Value